$30.16
-0.69 (-2.24%)
Open$31.04
Previous Close$30.85
Day High$31.15
Day Low$30.00
52W High$44.00
52W Low$14.00
Volume—
Avg Volume111.6K
Market Cap125.18M
P/E Ratio55.59
EPS$-0.92
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+11.3% upside
Current
$30.16
$30.16
Target
$33.56
$33.56
$24.17
$33.56 avg
$46.23
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 687.2K | 1.09M | 10.43M |
| Net Income | -12,476,417 | -17,738,981 | 2.46M |
| Profit Margin | -1,815.3% | -1,724.6% | 23.6% |
| EBITDA | -16,273,435 | -24,423,006 | 3.49M |
| Free Cash Flow | — | — | 3.25M |
| Rev Growth | -36.7% | -36.7% | +12.7% |
| Debt/Equity | — | — | 1.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |